Included in the formulation
АТХ:A.05.A.X.02 Gimecromone
Pharmacodynamics:Cholagogue preparation. Increases the formation and secretion of bile. Has a selective antispasmodic effect on the bile duct and sphincter of Oddi. The drug does not reduce peristalsis of the gastrointestinal tract and blood pressure.
Reduces stagnation of bile, prevents the crystallization of cholesterol and the formation of gallstones.
Pharmacokinetics:Suction and distribution
After oral administration, it is rapidly absorbed from the digestive tract. Cmax in the blood after ingestion is achieved after 2-3 hours.
Poorly binds to plasma proteins.
Excretion
Half-life is about 1 hour. It is excreted in urine: about 93% in the form of glucuronate, 1.4% in the form of sulfonate, 0.3% in unchanged form.
Indications:Dyskinesia of biliary tract and sphincter of Oddi in hyperkinetic type; non-calculous chronic cholecystitis, cholangitis, cholelithiasis; condition after surgery on the gallbladder and biliary tract; a decrease in appetite, nausea, constipation, vomiting (on the background of hypoxecretion of bile).
XI.K55-K63.K59.0 Constipation
XI.K80-K87.K80 Gallstone disease [cholelithiasis]
XI.K80-K87.K81.1 Chronic cholecystitis
XI.K80-K87.K82.8 Other specified diseases of the gallbladder
XI.K80-K87.K83.0 Cholangitis
XI.K90-K93.K91.5 Postcholecystectomy syndrome
XVIII.R10-R19.R11 Nausea and vomiting
Contraindications:Obstruction of bile ducts; kidney failure; liver failure; ulcerative colitis; Crohn's disease; peptic ulcer of the stomach and duodenum; hemophilia; children's age till 18 years; hypersensitivity to the components of the drug.
Carefully:The administration of the drug during pregnancy and lactation (breastfeeding) is only permissible if the intended benefit to the mother exceeds the potential risk to the fetus or the baby.
Pregnancy and lactation:There is no data on the safety of gemecromone during pregnancy and lactation. The administration of the drug during pregnancy and lactation (breastfeeding) is only permissible if the intended benefit to the mother exceeds the potential risk to the fetus or the baby.
Dosing and Administration:The drug is prescribed by mouth 30 minutes before meals.
Adults appoint 200-400 mg 3 times a day. The daily dose is 1200 mg. The course of treatment is 2 weeks.
Side effects:From the digestive system: diarrhea, flatulence, abdominal pain, ulceration of the gastrointestinal mucosa.
Other: allergic reactions, headache.
Overdose:At present, no cases of drug overdose have been reported.
Interaction:With simultaneous application morphine, causing a spasm of the sphincter of Oddi, weakens the action of gimecromone.
With the simultaneous use of the drug with metoclopramide, there is a mutual weakening of the effect.
The drug enhances the effects of indirect anticoagulants.
Special instructions:Does not impair the secretory function of the digestive glands and intestinal absorption processes.
Impact on the ability to drive vehicles and manage mechanisms
The drug does not affect the ability to drive vehicles and engage in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.